Keros Therapeutics Updates on Clinical Trials and Safety

TipRanksJan 10 08:31 ET

BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $33

Moomoo NewsJan 6 06:34 ET · Ratings

Keros Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesDec 23, 2024 07:51 ET · Ratings

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43

Moomoo NewsDec 23, 2024 07:33 ET · Ratings

Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating

MT NewswiresDec 23, 2024 06:52 ET · Ratings

Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential

TipRanksDec 23, 2024 06:45 ET · Ratings